The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

PolyNovo announced today a supply contract with the US Department of Defence. The deal allows US Defence facilities to purchase PolyNovo products for Veterans, active soldiers and military families.

The Australian medical device developers specialise in dermal regeneration solutions using patented biodegradable polymer technology. US Defence facilities will purchase PolyNovo products directly.

PolyNovo CEO Paul Brennan says the US military have been supportive of the company’s work with the Biomedical Advanced Research and Development Authority.

“This access offers significant opportunity for NovoSorb BTM in a large network of military health care facilities in the US and globally,” he said.

Current programs using the technology assist breast sling, hernia, and orthopaedic applications. The company’s leading product NovoSorb consists of bio-resorbable polymers that are produced in formats film, fibre, foam and coatings.

Chairman David Williams expressed delight at the option of patients to use the product through US Medicare.

“[NovoSorb] is such an important product that we want it to be available as widely as possible,” he said.

Earlier this year, PolyNovo signed a distribution deal with German company PolyMedics to supply products to Germany, Austria, Switzerland and Luxemburg. The European deal allowed a breakout distribution of PolyNovo products to burn victims.

Polynovo’s market cap currently sits at $684.2 million and trading shares at $1.04 per share as of this morning.

Please see announcement for further details

PNV by the numbers
More From The Market Herald

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…